25 XP   0   0   10

Grifols S.A.
Buy, Hold or Sell?

Let's analyse Grifols together

PenkeI guess you are interested in Grifols S.A.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Grifols S.A.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Grifols S.A.

I send you an email if I find something interesting about Grifols S.A..

Quick analysis of Grifols (30 sec.)










What can you expect buying and holding a share of Grifols? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
‚ā¨11.76
Expected worth in 1 year
‚ā¨8.93
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨-2.83
Return On Investment
-31.0%

For what price can you sell your share?

Current Price per Share
‚ā¨9.12
Expected price per share
‚ā¨6.362 - ‚ā¨10.18
How sure are you?
50%

1. Valuation of Grifols (5 min.)




Live pricePrice per Share (EOD)

‚ā¨9.12

Intrinsic Value Per Share

‚ā¨-6.28 - ‚ā¨1.09

Total Value Per Share

‚ā¨5.48 - ‚ā¨12.85

2. Growth of Grifols (5 min.)




Is Grifols growing?

Current yearPrevious yearGrowGrow %
How rich?$8.5b$9b-$504m-5.9%

How much money is Grifols making?

Current yearPrevious yearGrowGrow %
Making money$63.4m$222.7m-$159.3m-251.1%
Net Profit Margin0.9%3.4%--

How much money comes from the company's main activities?

3. Financial Health of Grifols (5 min.)




What can you expect buying and holding a share of Grifols? (5 min.)

Welcome investor! Grifols's management wants to use your money to grow the business. In return you get a share of Grifols.

What can you expect buying and holding a share of Grifols?

First you should know what it really means to hold a share of Grifols. And how you can make/lose money.

Speculation

The Price per Share of Grifols is ‚ā¨9.12. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Grifols.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Grifols, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨11.76. Based on the TTM, the Book Value Change Per Share is ‚ā¨-0.71 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.46 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Grifols.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps0.091.0%0.091.0%0.333.6%0.535.8%0.707.7%
Usd Book Value Change Per Share-0.76-8.3%-0.76-8.3%0.495.4%1.0511.5%0.9310.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.192.1%0.272.9%
Usd Total Gains Per Share-0.76-8.3%-0.76-8.3%0.495.4%1.2413.6%1.1913.1%
Usd Price Per Share16.53-16.53-11.52-21.05-25.71-
Price to Earnings Ratio176.94-176.94-35.08-67.11-51.39-
Price-to-Total Gains Ratio-21.88--21.88-23.37--480.46--216.93-
Price to Book Ratio1.31-1.31-0.86-1.83-3.79-
Price-to-Total Gains Ratio-21.88--21.88-23.37--480.46--216.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.755664
Number of shares102
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.19
Usd Book Value Change Per Share-0.761.05
Usd Total Gains Per Share-0.761.24
Gains per Quarter (102 shares)-77.08126.51
Gains per Year (102 shares)-308.32506.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-308-31878428496
20-617-6261568561002
30-925-93423512831508
40-1233-124231317112014
50-1542-155039121392520
60-1850-185846925673026
70-2158-216654829953532
80-2467-247462634224038
90-2775-278270438504544
100-3083-309078242785050

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.00.00.0100.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%14.05.00.073.7%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%9.00.01.090.0%17.00.02.089.5%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%8.02.00.080.0%15.04.00.078.9%

Fundamentals of Grifols

About Grifols S.A.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Fundamental data was last updated by Penke on 2024-06-16 18:59:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Grifols S.A..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Grifols earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Grifols to the¬†Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 0.9%¬†means that¬†€0.01 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Grifols S.A.:

  • The MRQ is 0.9%. The company is not making a profit/loss.
  • The TTM is 0.9%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ0.9%TTM0.9%0.0%
TTM0.9%YOY3.4%-2.5%
TTM0.9%5Y6.7%-5.8%
5Y6.7%10Y10.3%-3.6%
1.1.2. Return on Assets

Shows how efficient Grifols is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Grifols to the¬†Drug Manufacturers - General industry mean.
  • 0.3% Return on Assets means that¬†Grifols generated¬†€0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Grifols S.A.:

  • The MRQ is 0.3%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.3%TTM0.3%0.0%
TTM0.3%YOY1.0%-0.7%
TTM0.3%5Y2.1%-1.9%
5Y2.1%10Y3.8%-1.7%
1.1.3. Return on Equity

Shows how efficient Grifols is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Grifols to the¬†Drug Manufacturers - General industry mean.
  • 1.0% Return on Equity means Grifols generated €0.01¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Grifols S.A.:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.0%0.0%
TTM1.0%YOY3.4%-2.4%
TTM1.0%5Y6.8%-5.8%
5Y6.8%10Y11.5%-4.7%

1.2. Operating Efficiency of Grifols S.A..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Grifols is operating .

  • Measures how much profit Grifols makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Grifols to the¬†Drug Manufacturers - General industry mean.
  • An Operating Margin of 11.2%¬†means the company generated €0.11 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Grifols S.A.:

  • The MRQ is 11.2%. The company is operating less efficient.
  • The TTM is 11.2%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ11.2%TTM11.2%0.0%
TTM11.2%YOY13.3%-2.1%
TTM11.2%5Y15.5%-4.3%
5Y15.5%10Y19.4%-4.0%
1.2.2. Operating Ratio

Measures how efficient Grifols is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.89 means that the operating costs are €0.89 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Grifols S.A.:

  • The MRQ is 0.888. The company is less efficient in keeping operating costs low.
  • The TTM is 0.888. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.888TTM0.8880.000
TTM0.888YOY0.884+0.004
TTM0.8885Y0.851+0.037
5Y0.85110Y0.807+0.044

1.3. Liquidity of Grifols S.A..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Grifols is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Drug Manufacturers - General industry mean).
  • A Current Ratio of 2.79¬†means the company has €2.79 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Grifols S.A.:

  • The MRQ is 2.786. The company is able to pay all its short-term debts. +1
  • The TTM is 2.786. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.786TTM2.7860.000
TTM2.786YOY2.379+0.407
TTM2.7865Y2.609+0.177
5Y2.60910Y2.737-0.128
1.3.2. Quick Ratio

Measures if Grifols is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Grifols to the¬†Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.63¬†means the company can pay off €0.63 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Grifols S.A.:

  • The MRQ is 0.629. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.629. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.629TTM0.6290.000
TTM0.629YOY0.710-0.081
TTM0.6295Y1.416-0.787
5Y1.41610Y1.396+0.021

1.4. Solvency of Grifols S.A..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Grifols assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Grifols to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.63¬†means that Grifols assets are¬†financed with 62.8% credit (debt) and the remaining percentage (100% - 62.8%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Grifols S.A.:

  • The MRQ is 0.628. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.628. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.628TTM0.6280.000
TTM0.628YOY0.607+0.021
TTM0.6285Y0.586+0.042
5Y0.58610Y0.619-0.033
1.4.2. Debt to Equity Ratio

Measures if Grifols is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Grifols to the¬†Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 231.1% means that company has €2.31 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Grifols S.A.:

  • The MRQ is 2.311. The company is just not able to pay all its debts with equity.
  • The TTM is 2.311. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.311TTM2.3110.000
TTM2.311YOY2.133+0.178
TTM2.3115Y1.948+0.363
5Y1.94810Y1.940+0.008

2. Market Valuation of Grifols S.A.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Grifols generates.

  • Above 15 is considered overpriced but¬†always compare¬†Grifols to the¬†Drug Manufacturers - General industry mean.
  • A PE ratio of 176.94 means the investor is paying €176.94¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Grifols S.A.:

  • The EOD is 104.414. Based on the earnings, the company is expensive. -2
  • The MRQ is 176.943. Based on the earnings, the company is expensive. -2
  • The TTM is 176.943. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD104.414MRQ176.943-72.529
MRQ176.943TTM176.9430.000
TTM176.943YOY35.080+141.863
TTM176.9435Y67.107+109.836
5Y67.10710Y51.391+15.716
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Grifols S.A.:

  • The EOD is -71.076. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -120.447. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -120.447. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-71.076MRQ-120.447+49.371
MRQ-120.447TTM-120.4470.000
TTM-120.447YOY-18.908-101.539
TTM-120.4475Y12.121-132.568
5Y12.12110Y37.799-25.678
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Grifols is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 1.31 means the investor is paying €1.31¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Grifols S.A.:

  • The EOD is 0.775. Based on the equity, the company is cheap. +2
  • The MRQ is 1.314. Based on the equity, the company is underpriced. +1
  • The TTM is 1.314. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.775MRQ1.314-0.539
MRQ1.314TTM1.3140.000
TTM1.314YOY0.864+0.450
TTM1.3145Y1.832-0.518
5Y1.83210Y3.794-1.962
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Grifols S.A. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.706-0.7060%0.460-254%0.980-172%0.867-182%
Book Value Per Share--11.76011.7600%12.467-6%11.209+5%8.236+43%
Current Ratio--2.7862.7860%2.379+17%2.609+7%2.737+2%
Debt To Asset Ratio--0.6280.6280%0.607+3%0.586+7%0.619+1%
Debt To Equity Ratio--2.3112.3110%2.133+8%1.948+19%1.940+19%
Dividend Per Share----0%0.001-100%0.179-100%0.249-100%
Eps--0.0870.0870%0.307-72%0.496-82%0.658-87%
Free Cash Flow Per Share---0.128-0.1280%-0.570+344%0.208-162%0.407-132%
Free Cash Flow To Equity Per Share--0.1460.1460%-0.825+667%0.445-67%0.809-82%
Gross Profit Margin--0.9110.9110%-2.203+342%-0.129+114%0.435+109%
Intrinsic Value_10Y_max--1.085--------
Intrinsic Value_10Y_min---6.281--------
Intrinsic Value_1Y_max--0.344--------
Intrinsic Value_1Y_min---0.231--------
Intrinsic Value_3Y_max--0.853--------
Intrinsic Value_3Y_min---1.044--------
Intrinsic Value_5Y_max--1.147--------
Intrinsic Value_5Y_min---2.233--------
Market Cap3850327127.040-173%10495371171.94510495371171.9450%7306483174.380+44%13426457484.205-22%16437020226.417-36%
Net Profit Margin--0.0090.0090%0.034-74%0.067-87%0.103-91%
Operating Margin--0.1120.1120%0.133-16%0.155-28%0.194-42%
Operating Ratio--0.8880.8880%0.884+0%0.851+4%0.807+10%
Pb Ratio0.775-69%1.3141.3140%0.864+52%1.832-28%3.794-65%
Pe Ratio104.414-69%176.943176.9430%35.080+404%67.107+164%51.391+244%
Price Per Share9.120-69%15.45515.4550%10.770+44%19.682-21%24.037-36%
Price To Free Cash Flow Ratio-71.076+41%-120.447-120.4470%-18.908-84%12.121-1094%37.799-419%
Price To Total Gains Ratio-12.910+41%-21.877-21.8770%23.369-194%-480.463+2096%-216.925+892%
Quick Ratio--0.6290.6290%0.710-11%1.416-56%1.396-55%
Return On Assets--0.0030.0030%0.010-71%0.021-87%0.038-93%
Return On Equity--0.0100.0100%0.034-70%0.068-85%0.115-91%
Total Gains Per Share---0.706-0.7060%0.461-253%1.159-161%1.116-163%
Usd Book Value--8542936552.4008542936552.4000%9047034816.800-6%8163243114.360+5%6009523147.430+42%
Usd Book Value Change Per Share---0.756-0.7560%0.492-254%1.049-172%0.927-182%
Usd Book Value Per Share--12.58012.5800%13.336-6%11.990+5%8.810+43%
Usd Dividend Per Share----0%0.001-100%0.192-100%0.266-100%
Usd Eps--0.0930.0930%0.328-72%0.531-82%0.704-87%
Usd Free Cash Flow---93210448.900-93210448.9000%-413360961.900+343%152480814.380-161%298386503.770-131%
Usd Free Cash Flow Per Share---0.137-0.1370%-0.609+344%0.222-162%0.435-132%
Usd Free Cash Flow To Equity Per Share--0.1560.1560%-0.883+667%0.476-67%0.865-82%
Usd Market Cap4118694927.795-173%11226898542.63011226898542.6300%7815745051.634+44%14362281570.854-22%17582680536.198-36%
Usd Price Per Share9.756-69%16.53216.5320%11.521+44%21.054-21%25.712-36%
Usd Profit--63449255.50063449255.5000%222796046.300-72%380088585.220-83%490330048.730-87%
Usd Revenue--7051437796.9007051437796.9000%6486625499.900+9%5996265606.540+18%5152997884.050+37%
Usd Total Gains Per Share---0.756-0.7560%0.493-253%1.240-161%1.193-163%
 EOD+4 -4MRQTTM+0 -0YOY+12 -245Y+10 -2610Y+10 -26

3.2. Fundamental Score

Let's check the fundamental score of Grifols S.A. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15104.414
Price to Book Ratio (EOD)Between0-10.775
Net Profit Margin (MRQ)Greater than00.009
Operating Margin (MRQ)Greater than00.112
Quick Ratio (MRQ)Greater than10.629
Current Ratio (MRQ)Greater than12.786
Debt to Asset Ratio (MRQ)Less than10.628
Debt to Equity Ratio (MRQ)Less than12.311
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.003
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Grifols S.A. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.276
Ma 20Greater thanMa 509.231
Ma 50Greater thanMa 1009.134
Ma 100Greater thanMa 2009.204
OpenGreater thanClose8.990
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Other Stockholders Equity  -49,5845,850-43,734-120,455-164,1891,969-162,220860,885698,665



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets21,454,670
Total Liabilities13,468,378
Total Stockholder Equity5,827,166
 As reported
Total Liabilities 13,468,378
Total Stockholder Equity+ 5,827,166
Total Assets = 21,454,670

Assets

Total Assets21,454,670
Total Current Assets6,451,905
Long-term Assets15,002,765
Total Current Assets
Cash And Cash Equivalents 529,577
Short-term Investments 116,143
Net Receivables 810,860
Inventory 3,459,277
Other Current Assets 1,652,191
Total Current Assets  (as reported)6,451,905
Total Current Assets  (calculated)6,568,048
+/- 116,143
Long-term Assets
Property Plant Equipment 4,192,363
Goodwill 6,802,127
Long Term Investments 565,105
Intangible Assets 2,832,196
Long-term Assets Other 154,394
Long-term Assets  (as reported)15,002,765
Long-term Assets  (calculated)14,546,185
+/- 456,580

Liabilities & Shareholders' Equity

Total Current Liabilities2,315,604
Long-term Liabilities11,152,774
Total Stockholder Equity5,827,166
Total Current Liabilities
Short-term Debt 897,915
Short Long Term Debt 790,814
Accounts payable 813,114
Other Current Liabilities 565,382
Total Current Liabilities  (as reported)2,315,604
Total Current Liabilities  (calculated)3,067,225
+/- 751,621
Long-term Liabilities
Long term Debt 8,215,297
Capital Lease Obligations 1,111,328
Long-term Liabilities Other 814,069
Long-term Liabilities  (as reported)11,152,774
Long-term Liabilities  (calculated)10,140,694
+/- 1,012,080
Total Stockholder Equity
Common Stock119,604
Retained Earnings 59,315
Accumulated Other Comprehensive Income 4,949,582
Other Stockholders Equity 698,665
Total Stockholder Equity (as reported)5,827,166
Total Stockholder Equity (calculated)5,827,166
+/-0
Other
Capital Stock119,604
Cash and Short Term Investments 529,577
Common Stock Shares Outstanding 679,092
Current Deferred Revenue39,193
Liabilities and Stockholders Equity 21,454,670
Net Debt 9,587,862
Net Invested Capital 14,833,277
Net Working Capital 4,136,301
Property Plant and Equipment Gross 6,468,230
Short Long Term Debt Total 10,117,439



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-31
> Total Assets 
821,683
913,674
939,569
1,180,239
1,657,177
1,888,982
5,807,718
5,627,474
5,841,036
8,449,749
9,601,715
10,129,772
10,920,264
12,477,046
15,542,611
15,274,776
19,233,835
21,533,977
21,454,670
21,454,67021,533,97719,233,83515,274,77615,542,61112,477,04610,920,26410,129,7729,601,7158,449,7495,841,0365,627,4745,807,7181,888,9821,657,1771,180,239939,569913,674821,683
   > Total Current Assets 
436,294
473,294
495,527
626,600
1,004,578
1,144,082
1,929,215
1,934,564
2,139,660
2,913,122
3,089,472
3,122,514
2,945,316
3,483,251
5,362,184
3,164,954
5,510,280
4,653,587
6,451,905
6,451,9054,653,5875,510,2803,164,9545,362,1843,483,2512,945,3163,122,5143,089,4722,913,1222,139,6601,934,5641,929,2151,144,0821,004,578626,600495,527473,294436,294
       Cash And Cash Equivalents 
22,856
26,883
5,690
6,368
249,372
239,649
340,586
473,327
708,777
1,079,146
1,142,500
895,009
886,521
1,033,792
741,982
579,647
655,493
547,979
529,577
529,577547,979655,493579,647741,9821,033,792886,521895,0091,142,5001,079,146708,777473,327340,586239,649249,3726,3685,69026,88322,856
       Short-term Investments 
661
6,232
7,080
6,657
8,217
12,946
16,904
0
232
476
509
957
702
822
1,727,429
10,861
2,029,107
43,256
116,143
116,14343,2562,029,10710,8611,727,429822702957509476232016,90412,9468,2176,6577,0806,232661
       Net Receivables 
147,710
188,868
200,472
231,806
255,182
282,994
531,989
447,441
462,655
608,328
477,803
528,518
385,265
401,573
470,495
504,200
495,476
754,820
810,860
810,860754,820495,476504,200470,495401,573385,265528,518477,803608,328462,655447,441531,989282,994255,182231,806200,472188,868147,710
       Inventory 
249,545
235,475
270,659
373,098
484,462
527,865
1,030,341
998,644
946,913
1,194,057
1,431,391
1,642,931
1,629,293
1,949,360
2,342,590
2,002,281
2,259,354
3,201,357
3,459,277
3,459,2773,201,3572,259,3542,002,2812,342,5901,949,3601,629,2931,642,9311,431,3911,194,057946,913998,6441,030,341527,865484,462373,098270,659235,475249,545
       Other Current Assets 
8,186
7,706
11,626
8,671
7,345
80,628
9,395
20,805
21,315
23,669
31,091
48,324
32,354
42,344
58,111
51,750
64,079
81,814
1,652,191
1,652,19181,81464,07951,75058,11142,34432,35448,32431,09123,66921,31520,8059,39580,6287,3458,67111,6267,7068,186
   > Long-term Assets 
385,389
440,380
444,042
553,639
652,599
744,900
3,878,503
3,692,910
3,701,376
5,536,627
6,512,243
7,007,258
7,974,948
8,993,795
10,180,427
12,109,822
13,723,555
16,880,390
15,002,765
15,002,76516,880,39013,723,55512,109,82210,180,4278,993,7957,974,9487,007,2586,512,2435,536,6273,701,3763,692,9103,878,503744,900652,599553,639444,042440,380385,389
       Property Plant Equipment 
186,621
184,993
201,332
301,009
371,705
434,131
775,869
810,107
840,238
1,147,782
1,644,402
1,809,852
1,760,053
1,951,983
2,863,403
3,002,803
3,343,154
4,168,489
4,192,363
4,192,3634,168,4893,343,1543,002,8032,863,4031,951,9831,760,0531,809,8521,644,4021,147,782840,238810,107775,869434,131371,705301,009201,332184,993186,621
       Goodwill 
117,115
150,820
150,243
158,567
174,000
189,448
1,895,101
1,869,899
1,829,141
3,174,732
3,532,359
3,643,995
4,590,498
5,209,230
5,507,063
5,332,271
6,228,901
7,011,909
6,802,127
6,802,1277,011,9096,228,9015,332,2715,507,0635,209,2304,590,4983,643,9953,532,3593,174,7321,829,1411,869,8991,895,101189,448174,000158,567150,243150,820117,115
       Long Term Investments 
0
0
0
0
0
0
0
0
39,130
58,651
78,137
232,421
259,063
228,820
143,984
2,067,177
2,359,975
2,548,892
565,105
565,1052,548,8922,359,9752,067,177143,984228,820259,063232,42178,13758,65139,13000000000
       Intangible Assets 
48,718
60,850
57,223
57,756
69,385
78,299
1,008,307
969,095
946,435
1,068,361
1,161,572
1,195,302
1,269,342
1,385,537
1,433,534
1,557,650
1,636,950
2,949,147
2,832,196
2,832,1962,949,1471,636,9501,557,6501,433,5341,385,5371,269,3421,195,3021,161,5721,068,361946,435969,0951,008,30778,29969,38557,75657,22360,85048,718
       Other Assets 
0
0
0
0
0
0
0
0
46,432
132,363
140,910
156,107
328,337
505,430
564,251
812,555
882,614
174,923
0
0174,923882,614812,555564,251505,430328,337156,107140,910132,36346,43200000000
> Total Liabilities 
765,736
545,322
555,403
698,960
1,078,649
1,181,592
4,142,724
3,746,733
3,733,832
5,786,861
6,300,325
6,401,794
7,286,299
7,780,442
8,696,843
8,554,721
11,086,800
13,076,433
13,468,378
13,468,37813,076,43311,086,8008,554,7218,696,8437,780,4427,286,2996,401,7946,300,3255,786,8613,733,8323,746,7334,142,7241,181,5921,078,649698,960555,403545,322765,736
   > Total Current Liabilities 
252,405
282,764
316,576
317,538
299,043
423,126
646,077
592,865
715,296
1,079,711
1,053,006
1,071,763
977,987
1,257,321
1,366,558
1,335,138
3,474,312
1,955,847
2,315,604
2,315,6041,955,8473,474,3121,335,1381,366,5581,257,321977,9871,071,7631,053,0061,079,711715,296592,865646,077423,126299,043317,538316,576282,764252,405
       Short-term Debt 
103,635
138,881
183,992
151,710
113,991
191,635
147,789
192,003
251,389
165,860
186,797
203,944
133,067
268,199
320,802
319,571
2,394,182
681,273
897,915
897,915681,2732,394,182319,571320,802268,199133,067203,944186,797165,860251,389192,003147,789191,635113,991151,710183,992138,881103,635
       Short Long Term Debt 
0
0
0
0
0
0
0
0
2,730,711
154,567
188,073
200,085
129,122
264,851
276,397
276,929
2,345,615
578,917
790,814
790,814578,9172,345,615276,929276,397264,851129,122200,085188,073154,5672,730,71100000000
       Accounts payable 
70,587
81,513
76,934
99,215
120,909
160,678
280,722
228,405
273,621
439,631
409,986
461,073
423,096
561,883
581,882
601,618
628,992
731,918
813,114
813,114731,918628,992601,618581,882561,883423,096461,073409,986439,631273,621228,405280,722160,678120,90999,21576,93481,51370,587
       Other Current Liabilities 
26,161
17,256
23,702
29,725
12,230
18,236
101,993
6,243
182,823
453,847
447,032
399,742
407,595
411,714
453,236
389,969
407,599
504,822
565,382
565,382504,822407,599389,969453,236411,714407,595399,742447,032453,847182,8236,243101,99318,23612,23029,72523,70217,25626,161
   > Long-term Liabilities 
513,331
262,558
238,827
381,422
779,606
758,466
3,496,647
3,153,868
3,018,536
4,707,150
5,247,319
5,330,031
6,308,312
6,523,121
7,330,285
7,219,583
7,612,488
11,120,586
11,152,774
11,152,77411,120,5867,612,4887,219,5837,330,2856,523,1216,308,3125,330,0315,247,3194,707,1503,018,5363,153,8683,496,647758,466779,606381,422238,827262,558513,331
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,885,043
7,179,483
9,068,852
0
09,068,8527,179,4836,885,043000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
536,531
601,091
675,473
648,935
430,134
502,613
544,198
627,755
682,364
2,051,734
0
02,051,734682,364627,755544,198502,613430,134648,935675,473601,091536,53100000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
45,262
45,137
70,620
232,345
287,205
331,808
575,515
633,240
1,622,641
0
01,622,641633,240575,515331,808287,205232,34570,62045,13745,262000000000
> Total Stockholder Equity
55,826
367,944
383,185
480,029
566,371
693,040
1,662,507
1,876,768
2,101,262
2,658,123
3,296,203
3,721,481
3,629,079
4,225,554
4,822,119
5,108,392
6,096,643
6,129,938
5,827,166
5,827,1666,129,9386,096,6435,108,3924,822,1194,225,5543,629,0793,721,4813,296,2032,658,1232,101,2621,876,7681,662,507693,040566,371480,029383,185367,94455,826
   Common Stock
70,169
106,532
106,532
106,532
0
0
117,882
1,008,237
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
119,604
119,6041,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,008,237117,88200106,532106,532106,53270,169
   Retained Earnings 
25,556
45,394
0
0
147,972
115,513
50,307
256,686
276,796
384,309
412,530
422,548
539,714
459,895
488,318
618,546
182,803
208,279
59,315
59,315208,279182,803618,546488,318459,895539,714422,548412,530384,309276,796256,68650,307115,513147,9720045,39425,556
   Accumulated Other Comprehensive Income 
-39,899
216,018
85,940
163,054
224,650
352,871
627,074
614,905
794,134
1,312,734
1,911,916
2,337,311
2,121,455
2,790,768
3,353,053
3,503,248
5,047,697
5,053,547
4,949,582
4,949,5825,053,5475,047,6973,503,2483,353,0532,790,7682,121,4552,337,3111,911,9161,312,734794,134614,905627,074352,871224,650163,05485,940216,018-39,899
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
910,728
910,728
910,728
0
0910,728910,728910,728000000000000000
   Treasury Stock0000000000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.